Stockreport

Amylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]

Amylyx Pharmaceuticals, Inc.  (AMLX) 
PDF Total Operating Expenses (Q4 2024): $39.9 million, down 62% from Q4 2023. Research and Development Expenses (Q4 2024): $22.9 million, compared to $44.9 million in Q4 [Read more]